Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Type 2 Diabetes

In brief

This is a Phase 2, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes who are not achieving glycemic targets despite antihyperglycemic medications.

Key facts

Study ID
NCT07502495
Run by
Biomea Fusion Inc.
People needed
60
Starts
2026-03-27
Expected to finish
2027-09-01
Last updated by the study team
2026-08-07

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.